Tags : PSMA Diagnostic

GE Healthcare Signs a Worldwide Development and Commercialization Agreement with

Shots: The companies enter into a global commercialization agreement for new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. GE Healthcare to take care of all pre-approval commercial preparations plus all subsequent commercial and distribution activities. Theragnostics to lead the development of the tracer, GalliProst (Gallium-68 (68Ga) diagnostic tracer) benefiting treatments for Prostate Cancer   The companies […]Read More